Scotland has taken a groundbreaking step by initiating screening for a rare disorder in newborns, heralded by parents as a significant development. The condition, known as Spinal Muscular Atrophy (SMA), can lead to muscle deterioration, breathing difficulties, swallowing problems, and reduced mobility in children. Detecting SMA early can help prevent the severe consequences associated with the disorder. On average, about three to four infants are born with SMA each year in Scotland.

Parents will now have the opportunity to have their newborns screened for SMA using the existing blood spot test typically performed around the fourth day after birth. This move aligns with The Mirror’s advocacy for nationwide testing of all newborns in the UK for SMA, a campaign that gained momentum five years ago. Singer Jesy Nelson, formerly of Little Mix and mother to twins affected by SMA, collaborated with The Mirror earlier this year to advocate for universal screening of babies.

Carrie and Tony Pearson’s daughter, Grayce, was diagnosed with SMA type two at around six months old after experiencing a progressive loss of leg movement and strength. Since then, the Pearsons have been campaigning for a national screening program to detect SMA in infants.

Carrie expressed gratitude for the screening program’s implementation, highlighting the relief that future children will receive timely treatment and avoid the challenges their family faced. Tony emphasized the historic nature of the pilot program in Scotland, underscoring the minimal cost of £4 per baby test compared to the invaluable impact on children’s lives.

Dr. Sarah Smith, the director of the Glasgow screening laboratory, emphasized the program’s goal to identify SMA in infants before symptoms manifest, thereby preventing muscle wastage. The laboratory, situated near the Queen Elizabeth University Hospital, already screens for ten disorders and will now include SMA in its screening process.

Funded by the Scottish Government and Novartis, the two-year pilot scheme aims to identify SMA pre-symptomatically in infants, enabling early intervention to enhance their quality of life by minimizing the impact of the condition’s symptoms.